Patent Number: 9,803,021

Title: CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-.alpha.) or to a mutant interferon alpha.

Inventors: Morrison; Sherie L. (Los Angeles, CA)

Assignee: The Regents of the University of California

International Classification: A61K 38/21 (20060101); C07K 16/30 (20060101); C07K 14/56 (20060101); A61K 39/00 (20060101); A61K 39/395 (20060101); C07K 16/32 (20060101); A61K 45/06 (20060101); C07K 14/565 (20060101); C07K 16/46 (20060101); C07K 19/00 (20060101); C07K 16/28 (20060101); C07K 14/555 (20060101); A61P 35/00 (20060101); C07K 14/57 (20060101); A61K 38/00 (20060101)

Expiration Date: 2021-10-31 0:00:00